ZC3H7B

Across TCGA pan-cancer cohorts, ZC3H7B mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ZC3H7B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ZC3H7B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ZC3H7B is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where ZC3H7B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZC3H7B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.315	<.001	11	view →
LUAD	Male	II,III,IV	+0.184	<.001	9	view →
LSCC	All	All	+0.167	<.001	7	view →
PDAC	All	All	−0.168	.002	5	view →
CCRCC	Male	All	−0.052	.022	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ZC3H7B–HNSC

Open the HNSC breakdown →